Anxiety

MELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, the Company's oral fixed-dose combination product candidate for the treatment of obstructive sleep a

Psilocybin—the psychedelic compound that occurs naturally in certain "magic" mushroom species—has been shown in trials to provide long-term treatment for depression and anxiety. But the chemical's hallucinogenic effects can make developing treatments expensive and pose significant risks to people living with other psychiatric illnesses.

-- Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 -- -- Enrolling Phase 2 REKINDLE Trial of RE104 in Adjustment Disorder (AjD); Initial Data Expected in 1Q 2027 ---- On Track to Initiate Phase 2 RECLAIM Trial in Generalized Anxiety Disorder (GAD) in 1Q 2026 -- MORRISTOWN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company co

LSD became notorious during the drug culture of the 1960s as a powerful hallucinogen. But a form of that drug shows promise for treating anxiety and is now being tested in Charleston and elsewhere.

There is a link between mental health and heart health. That means treating anxiety, depression, or PTSD may help prolong your life.

(MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (–AtaiBeckley– or the–Company–), a clinical-stage biotechnology company on a mission to ...

LifeStance Health reports new anxiety medications are expected for 2026, featuring innovative treatments in clinical trials that could reshape care.

In fiscal year 2025, UNC School of Medicine researchers led the drive toward important discoveries aimed at improving human health and the lives of people in North Carolina. Our researchers remain dedicated to UNC’s broader research missions by preventing and curing disease, optimizing brain health and well-being, and applying artificial intelligence to benefit and save lives.Continue reading

Getting stuck in a negative loop is part of many mental health disorders. A new therapy focuses more on these thought patterns than the thoughts themselves.

While GLP-1 drugs promise an easy fix, our bodies still need what they have always needed: healthy food and regular exerciseProf Devi Sridhar is chair of global public health at the University of EdinburghIf there has been a hot topic in health in 2025, it’s definitely been GLP-1s, colloquially referred to as “anti-obesity” jabs. These medications, taken weekly as an injection into the abdomen, result in significant weight loss and, despite being developed to manage type 2 diabetes in those with